NASDAQ:TNGX Tango Therapeutics (TNGX) Stock Price, News & Analysis $23.02 -0.46 (-1.96%) Closing price 04:00 PM EasternExtended Trading$23.02 0.00 (0.00%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tango Therapeutics Stock (NASDAQ:TNGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tango Therapeutics alerts:Sign Up Key Stats Today's Range$22.92▼$23.9150-Day Range$11.14▼$27.7752-Week Range$1.07▼$28.41Volume1.51 million shsAverage Volume3.29 million shsMarket Capitalization$3.32 billionP/E RatioN/ADividend YieldN/APrice Target$22.44Consensus RatingModerate Buy Company Overview Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition. The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues. Tango has entered strategic collaborations with major pharmaceutical partners to advance these programs, most notably a multi-asset agreement with GSK to discover and develop DNA damage response inhibitors and a partnership with Merck focused on novel synthetic lethal targets in oncology. These alliances provide access to additional computational tools, screening libraries and global development expertise. Founded in 2019 as a spin-out from Dana-Farber Cancer Institute and Harvard Medical School, Tango Therapeutics is headquartered in Cambridge, Massachusetts, near one of the world’s leading biopharma clusters. The management team combines scientific founders with broad drug development experience, enabling the company to rapidly translate genetic insights into translational programs. Tango has assembled an advisory board of academic and industry experts to guide target selection and clinical strategy. With its concentrated focus on synthetic lethality, Tango Therapeutics seeks to address unmet needs in solid tumors and hematologic cancers driven by specific genetic lesions. The company is advancing its pipeline through IND-enabling studies and early clinical trials, aiming to validate its approach of pairing genomic profiling with highly selective therapies. Tango’s platform is designed to uncover novel treatment modalities that could extend the benefits of precision oncology to patient populations beyond those served by current standard-of-care agents.AI Generated. May Contain Errors. Read More Tango Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreTNGX MarketRank™: Tango Therapeutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 762nd out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingTango Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Tango Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageTango Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tango Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.35) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tango Therapeutics is -26.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tango Therapeutics is -26.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTango Therapeutics has a P/B Ratio of 8.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tango Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for TNGX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTango Therapeutics does not currently pay a dividend.Dividend GrowthTango Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.29 News SentimentTango Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Tango Therapeutics this week, compared to 4 articles on an average week.Search Interest11 people have searched for TNGX on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tango Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,346,181.00 in company stock.Percentage Held by Insiders6.50% of the stock of Tango Therapeutics is held by insiders.Percentage Held by Institutions78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tango Therapeutics' insider trading history. Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNGX Stock News HeadlinesTango Therapeutics (NASDAQ:TNGX) Insider Sells $573,210.00 in StockMay 8 at 4:48 AM | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 27,000 SharesMay 6 at 6:03 AM | insidertrades.comPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.May 8 at 1:00 AM | Weiss Ratings (Ad)Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comWhy this CEO is confident his drug can top 'unprecedented' pancreatic cancer resultsApril 30, 2026 | msn.comTango Therapeutics (TNGX) price target increased by 11.68% to 24.38April 28, 2026 | msn.comIs Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines?April 20, 2026 | finance.yahoo.comTango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 38,460 SharesApril 17, 2026 | insidertrades.comSee More Headlines TNGX Stock Analysis - Frequently Asked Questions How have TNGX shares performed this year? Tango Therapeutics' stock was trading at $8.86 on January 1st, 2026. Since then, TNGX shares have increased by 159.8% and is now trading at $23.02. How were Tango Therapeutics' earnings last quarter? Tango Therapeutics, Inc. (NASDAQ:TNGX) posted its earnings results on Thursday, March, 5th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative net margin of 151.15% and a negative trailing twelve-month return on equity of 50.30%. When did Tango Therapeutics IPO? Tango Therapeutics (TNGX) raised $145 million in an initial public offering (IPO) on Thursday, September 3rd 2020. The company issued 14,500,000 shares at a price of $10.00 per share. Who are Tango Therapeutics' major shareholders? Top institutional investors of Tango Therapeutics include TRV GP IV LLC (4.42%), Candriam S.C.A. (0.88%), Dimensional Fund Advisors LP (0.34%) and Bank of New York Mellon Corp (0.22%). Insiders that own company stock include Rock Ventures Iv LP Third, Boxer Capital, Llc, Boxer Capital Management, Llc, Barbara Weber, Mva Investors, Llc, Daniella Beckman, Adam Crystal, Douglas Barry and Mace Rothenberg. View institutional ownership trends. How do I buy shares of Tango Therapeutics? Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tango Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tango Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings3/05/2026Today5/08/2026Next Earnings (Estimated)5/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 TNGX's financial health is in the Green zone, according to TradeSmith. TNGX has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNGX CIK1819133 Webwww.tangotx.com Phone857-320-4900FaxN/AEmployees90Year Founded2017Price Target and Rating Average Price Target for Tango Therapeutics$22.44 High Price Target$40.00 Low Price Target$14.00 Potential Upside/Downside-2.5%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$101.59 million Net Margins-151.15% Pretax Margin-162.85% Return on Equity-50.30% Return on Assets-36.25% Debt Debt-to-Equity RatioN/A Current Ratio16.32 Quick Ratio16.32 Sales & Book Value Annual Sales$62.38 million Price / Sales53.23 Cash FlowN/A Price / Cash FlowN/A Book Value$2.57 per share Price / Book8.96Miscellaneous Outstanding Shares144,240,000Free Float134,866,000Market Cap$3.32 billion OptionableOptionable Beta1.22 Social Links 10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:TNGX) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | SponsoredJPMorgan Just Made $6,300 Gold Call. Are You Exposed?JPMorgan just raised its 2026 gold forecast to 6,300 - and outlined a credible path to 8,000 if everyday inves...Vault Metal | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
